Hans Pharmaceuticals (03692): The approval of the listing of Ameitni hydrochloride tablets by the UK Medicines and Healthcare products Regulatory Agency.

Zhtng Cijng APP news, Hnshn Zhyo (03692) announced that the innovative drug Aumseqa (Afatinib) has been approved for marketing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Aumseqa is indicated as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for the treatment of adult patients with locally advanced or metastatic NSCLC who have the EGFR T790M mutation.